Fortress Biotech, Inc. (FBIO)
NASDAQ (CM) NASDAQ (CM) Primary 
Fortress Biotech, Inc. (FBIO) Q4 2024 Earnings Call Transcript
Fortress Biotech, Inc. (NASDAQ:FBIO ) Q4 2024 Earnings Conference Call March 26, 2025 4:30 PM ET Company Participants Jaclyn Jaffe - Senior Director, Corporate Operations Claude Maraoui - Co-Founder, President and CEO Joseph Benesch - CFO Srinivas Sidgiddi - VP, R&D Louis Donati - Director, Market Access Conference Call Participants Thomas Flaten - Lake Street Capital Markets Scott Henry - AGP Brandon Folkes - Rodman & Renshaw Jason Wittes - ROTH Capital Kalpit Patel - B. Riley Securities Operator Ladies and gentlemen, thank you for standing by.
Fortress Biotech (FBIO) Shows Fast-paced Momentum But Is Still a Bargain Stock
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Fortress Biotech (FBIO) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Fortress Biotech (FBIO) Reports Q2 Loss, Lags Revenue Estimates
Fortress Biotech (FBIO) came out with a quarterly loss of $0.73 per share versus the Zacks Consensus Estimate of a loss of $1.32. This compares to loss of $3.60 per share a year ago.
Here Is Why Bargain Hunters Would Love Fast-paced Mover Fortress Biotech (FBIO)
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Fortress Biotech (FBIO) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
